checkAd

Molecular Stethoscope Announces Publication of its NAFLD/NASH Study in the American Journal of Physiology - Gastrointestinal and Liver Physiology - Seite 2

Nachrichtenquelle: PR Newswire (engl.)
23.02.2021, 09:00  |  101   |   |   

"The publication of this important study positions us to move forward with the next phase of product development to have a significant impact on NAFLD/NASH clinical practice and in Pharma/Biotech R&D to improve the health of patients," commented Guillermo Elias, Ph.D., Chief Executive Officer at Molecular Stethoscope.

The study is available at the American Journal of Physiology - Gastrointestinal and Liver Physiology website.

https://journals.physiology.org/doi/abs/10.1152/ajpgi.00397.2020

"We would like to thank the contributions of our medical and scientific collaborators and NAFLD/NASH patients for participating in this study," acknowledged Dr. Elias, CEO of Molecular Stethoscope.

About Molecular Stethoscope
Molecular Stethoscope is a precision medicine company based in Silicon Valley, California, focused on discovering, developing and commercializing non-invasive and dynamic products for the early detection, diagnosis and treatment-response monitoring of chronic diseases starting with the liver (NAFLD/NASH) and the central nervous system (Alzheimer's Disease and Multiple Sclerosis). Molecular Stethoscope was co-founded by Dr. Stephen Quake, Professor of Bioengineering at Stanford University, and co-President of the Chan Zuckerberg BioHub, and Dr. Eric Topol, Director and Founder, Scripps Research Translational Institute; Chair of Innovative Medicine, Scripps. The Company's proprietary and novel Next-Generation cf-mRNA Liquid Biopsy-Artificial Intelligence Technology Platform integrates cell-free mRNA (cf-mRNA) with RNA-Seq, clinical information, and purpose-built bioinformatics and machine learning and artificial intelligence to generate clinically actionable, dynamic information to fundamentally change how healthcare is delivered at scale.

Forward Looking Statement
This press release contains forward-looking statements including, but not limited to statements about the Company's expectations regarding its proprietary Technology Platform. Forward looking statements are subject to uncertainties that could cause actual performance or results to differ materially from those expressed in the forward-looking statements.

Additional information and inquiries

Investor Relations: investorrelations@molecularstethoscope.com

Public and Media Relations: publicrelations@molecularstethoscope.com

Logo - https://mma.prnewswire.com/media/353332/Molecular_Stethoscope_Inc_Logo.jpg  

Seite 2 von 2



0 Kommentare

Schreibe Deinen Kommentar

Bitte melden Sie sich an, um zu kommentieren. Anmelden | Registrieren

 

Disclaimer

Molecular Stethoscope Announces Publication of its NAFLD/NASH Study in the American Journal of Physiology - Gastrointestinal and Liver Physiology - Seite 2 Circulating cell-free mRNA in blood reflective of NAFLD/NASH liver pathology PALO ALTO, Calif., Feb. 23, 2021 /PRNewswire/ - Molecular Stethoscope, Inc., a precision medicine biotechnology company, announces publication of its human …

Nachrichten des Autors

Titel
Titel
Titel
Titel